EUR 0.01
(-5.71%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 7.58 Million EUR | 227.14% |
2022 | 2.31 Million EUR | -82.2% |
2021 | 13.02 Million EUR | -18.67% |
2020 | 16.01 Million EUR | 43.34% |
2019 | 11.17 Million EUR | -10.36% |
2018 | 12.46 Million EUR | 1.06% |
2017 | 12.33 Million EUR | -3.63% |
2016 | 12.79 Million EUR | 4.7% |
2015 | 12.22 Million EUR | 117.32% |
2014 | 5.62 Million EUR | 39.09% |
2013 | 4.04 Million EUR | 10.43% |
2012 | 3.66 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 1.58 Million EUR | 0.0% |
2024 Q1 | 1.58 Million EUR | -4.73% |
2023 FY | 7.34 Million EUR | 217.0% |
2023 Q1 | 10.16 Million EUR | 925.33% |
2023 Q2 | 4.16 Million EUR | -59.01% |
2023 Q3 | 1.67 Million EUR | -59.74% |
2023 Q4 | 1.65 Million EUR | -1.07% |
2022 Q4 | 990.99 Thousand EUR | 0.0% |
2022 FY | 2.31 Million EUR | -82.2% |
2022 Q3 | 990.99 Thousand EUR | -76.64% |
2022 Q2 | 4.24 Million EUR | 0.0% |
2021 Q4 | 8.2 Million EUR | 0.0% |
2021 FY | 13.02 Million EUR | -18.67% |
2021 Q2 | 6.43 Million EUR | 0.0% |
2020 Q4 | 8.54 Million EUR | 0.0% |
2020 FY | 16.01 Million EUR | 43.34% |
2020 Q2 | 9.78 Million EUR | 0.0% |
2019 FY | 11.17 Million EUR | -10.36% |
2019 Q2 | 6.72 Million EUR | 0.0% |
2019 Q4 | 7.01 Million EUR | 0.0% |
2018 Q4 | 8.29 Million EUR | 0.0% |
2018 FY | 12.46 Million EUR | 1.06% |
2017 FY | 12.33 Million EUR | -3.63% |
2016 FY | 12.79 Million EUR | 4.7% |
2015 FY | 12.22 Million EUR | 117.32% |
2014 Q3 | 1.08 Million EUR | 0.0% |
2014 FY | 5.62 Million EUR | 39.09% |
2014 Q4 | 1.88 Million EUR | 73.75% |
2013 Q4 | 1.31 Million EUR | 0.0% |
2013 FY | 4.04 Million EUR | 10.43% |
2012 FY | 3.66 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -81.542% |
ABIVAX Société Anonyme | 127.37 Million EUR | 94.047% |
Adocia SA | 15.62 Million EUR | 51.481% |
Aelis Farma SA | 18.81 Million EUR | 59.706% |
Biophytis S.A. | 14.33 Million EUR | 47.094% |
Advicenne S.A. | 8.21 Million EUR | 7.693% |
genOway Société anonyme | 16.73 Million EUR | 54.697% |
IntegraGen SA | 5.35 Million EUR | -41.672% |
Medesis Pharma S.A. | 1.56 Million EUR | -384.669% |
Neovacs S.A. | 10.34 Million EUR | 26.689% |
NFL Biosciences SA | 4.37 Million EUR | -73.351% |
Plant Advanced Technologies SA | 2.76 Million EUR | -174.264% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -341.394% |
Sensorion SA | 27.05 Million EUR | 71.971% |
Theranexus Société Anonyme | 3 Million EUR | -152.347% |
TME Pharma N.V. | 5.49 Million EUR | -37.948% |
Valbiotis SA | 9.86 Million EUR | 23.163% |
TheraVet SA | 1.64 Million EUR | -361.165% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 62.682% |
argenx SE | 1.34 Billion EUR | 99.435% |
Celyad Oncology SA | 8.49 Million EUR | 10.683% |
DBV Technologies S.A. | 89.4 Million EUR | 91.518% |
Galapagos NV | 327.98 Million EUR | 97.688% |
Genfit S.A. | 54.8 Million EUR | 86.163% |
GeNeuro SA | 14.35 Million EUR | 47.184% |
Hyloris Pharmaceuticals SA | 17.98 Million EUR | 57.842% |
Innate Pharma S.A. | 64.57 Million EUR | 88.256% |
Inventiva S.A. | 120.18 Million EUR | 93.691% |
MaaT Pharma SA | 21.59 Million EUR | 64.89% |
MedinCell S.A. | 32.92 Million EUR | 76.967% |
Nanobiotix S.A. | 58.92 Million EUR | 87.132% |
Onward Medical N.V. | 20.64 Million EUR | 63.27% |
Oryzon Genomics S.A. | 18.49 Million EUR | 59.004% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 67.854% |
Oxurion NV | 12.21 Million EUR | 37.916% |
Pharming Group N.V. | 204.24 Million EUR | 96.287% |
Poxel S.A. | 28.76 Million EUR | 73.638% |
GenSight Biologics S.A. | 32.66 Million EUR | 76.782% |
Transgene SA | 31.23 Million EUR | 75.72% |
Financière de Tubize SA | 114.38 Thousand EUR | -6529.134% |
UCB SA | 2.94 Billion EUR | 99.742% |
Valneva SE | 134.92 Million EUR | 94.38% |
Vivoryon Therapeutics N.V. | 24.69 Million EUR | 69.29% |